Search

Researchers have submitted a patent application for a novel method of detecting nucleic acids in samples without the need for intensive preparation or amplification. This method allows for rapid and sensitive detection of target nucleic acids, including viral RNA, with high specificity. The inventors have developed a technique that involves excising and detecting specific target probes from the nucleic acids, enabling multiplexing and quantification of target nucleic acids in a sample. [Extracted from the article]

A patent application titled "Methods For Identifying A Location Of An Rna In A Biological Sample" has been published online by the US Patent and Trademark Office. The patent application, filed by inventor Marlon Stoeckius, describes methods for improving the efficiency of adding a sequencing oligonucleotide to a cDNA generated on a spatial array. The methods involve using RNAse H or a functional equivalent to produce nicks in the RNA of a RNA:DNA hybrid, followed by end repair, A-tailing, and ligation of a double-stranded adaptor to a blunt-ended double-stranded DNA product. These methods can be used to identify the location of an RNA in a biological sample. The assignee for this patent application is 10X Genomics Inc. [Extracted from the article]

Researchers at Sichuan University in Chengdu, China have developed a bioswitchable delivery system for microRNA (miRNA) therapeutics using a tetrahedral DNA nanostructure. This system allows for controlled loading and release of miRNA regulators, which play a role in regulating physiological and pathological activities in the human body. The researchers provide two design strategies for the bioswitchable delivery system, both of which show promising results in terms of cellular membrane permeability, tissue permeability, and target inhibition. This research offers potential advancements in the field of nucleic acid drug development. [Extracted from the article]

Creyon Bio Inc. has been issued a patent for a machine learning method that aims to develop more efficient and cost-effective oligonucleotide-based medicines (OBMs). The method involves training a machine-learned model to predict the pharmacology of OBMs and generate precise nucleic acid interactions. This technology has the potential to accelerate the development of new drugs and diagnostic instruments. The patent also describes a method for generating a final set of oligonucleotides using the trained model, which can be used for various purposes such as aptamers, antisense oligonucleotides, and gene-editing. The machine-learned model is trained using a regression model and can be iteratively trained until a stop condition is satisfied. [Extracted from the article]

Researchers from the University of Pittsburgh School of Medicine have discovered benzisothiazolone derivatives that have the potential to inhibit the ribonuclease H (RNase H) activity of HIV-1 reverse transcriptase (RT). This is significant because the RNase H active site is the only viral enzyme not targeted by approved antiretroviral drugs. The researchers identified four compounds that demonstrated inhibition of RT RNase H activity and virus replication, with three of them also inhibiting the DNA polymerase activity of RT. These benzisothiazolone derivatives represent a new class of multifunctional RT inhibitors that could be further assessed for the treatment of HIV-1 infection. [Extracted from the article]

New York University has been issued a patent for methods, procedures, and kits that provide maximum depth enrichment sequencing for the identification of rare genomic variants. Existing methods for detecting rare mutants in DNA sequences are expensive and inefficient. This patent addresses these deficiencies by introducing a method that utilizes barcoding techniques to decrease error rates and increase sensitivity in detecting rare genomic variants. The method involves digesting the nucleic acid, performing linear amplification with barcoded adapters, removing unused barcodes, performing mutant enrichment, and sequencing the resulting library. This patent offers a potential solution for improving the detection of rare genomic variants in cancer prognosis and other applications. [Extracted from the article]

A new report from Gifu University in Japan discusses research on biotechnology and the development of antisense oligonucleotides (ASOs) as potential therapeutic agents for genetic disorders and life-threatening conditions. The researchers synthesized modified oligonucleotides containing new analogs and found that they exhibited improved stability and activity. These analogs also enhanced the serum stability of the modified oligodeoxynucleotides. The study concludes that these analogs have potential as ASO therapeutic candidates. The research has been peer-reviewed and published in ChemistrySelect. [Extracted from the article]

A recent study conducted by researchers at the National and Kapodistrian University of Athens has explored the potential of N-hydroxypyridinedione (HPD) compounds as inhibitors of the Hepatitis B virus (HBV) RNase H enzyme. The researchers designed and synthesized 18 novel HPD oximes, as well as other related compounds, and found that all of them effectively inhibited viral replication in cell assays. These compounds exhibited low cytotoxicity and high selectivity indexes, making them promising candidates for the development of potent anti-HBV agents. This research contributes to the understanding of the structure-activity relationships of HPD compounds and their potential as therapeutic agents for HBV. [Extracted from the article]

A recent study conducted by researchers at Fudan University in Shanghai, China, focused on the development of novel RNase H inhibitors for HIV therapy. The researchers identified a series of thiazolone[3,2-a]pyrimidine-containing compounds that exhibited inhibitory activity against RNase H, with compound 12b being the most potent inhibitor. The study also conducted docking studies and a quantitative structure-activity relationship analysis to understand the interactions and predict the activity of the compounds. The researchers concluded that thiazolone[3,2-a]pyrimidine could serve as a potential scaffold for the further development of RNase H inhibitors. [Extracted from the article]

A patent has been issued to the University of California for fusion proteins and methods for site-directed genome editing. The patent describes methods for modifying a target site within a DNA-RNA hybrid molecule using adenosine deaminase. The invention aims to improve the efficiency and specificity of genome editing techniques by introducing mutations without breaking the DNA strand. The fusion proteins described in the patent can be used in vitro or within cells, including eukaryotic cells, and have potential applications in biotechnology and genetics. [Extracted from the article]

A recent study conducted by investigators from Murdoch University in Australia explores the potential of chemically modified antisense oligonucleotides (ASOs) as a therapeutic strategy for cancer treatment. While ASOs have been successful in treating various human diseases, none have been approved for cancer therapy. The researchers developed steric-blocking ASOs targeting the BIRC5 oncogene and identified two candidates, ASO-2 and ASO-7, that efficiently inhibited the production of BIRC5 mRNA in HepG2 cells. Further analysis confirmed that ASO-7 significantly repressed survivin production on the protein level. The researchers believe that ASO-7 could be a useful BIRC5 inhibitor for both research purposes and therapeutic development. [Extracted from the article]

A patent application by Riken inventors has been made available online, discussing the use of antisense oligonucleotide (ASO) treatment for myotonic dystrophy type 1 (DM1). The application explores modifications of nucleotides used in ASOs and discusses the design of ASOs with different properties. It also mentions the use of patient-derived induced pluripotent stem cells (iPSCs) for drug discovery and development. The patent application describes a pharmaceutical composition for treating DM1 disease, containing an oligonucleotide with a repeated sequence of cytosine-adenine-guanine trinucleotides. The composition can be delivered through various routes of administration and used to treat the symptoms of DM1 disease. [Extracted from the article]

Emory University has been issued a patent for polynucleotide-based movement, kits, and methods related to it. The patent describes a method for moving particles or rods coated with single-stranded DNA along a surface coated with single-stranded RNA using an endoribonuclease called RNase H. The movement of the particles or rods is influenced by the complementarity of the DNA and RNA sequences. This technology has potential applications in areas such as sensors, drug delivery platforms, and computing. The patent provides detailed information on the method and its various embodiments. [Extracted from the article]

In some embodiments, the HBV polymerase deletion mutant polypeptide comprises in sequential order from the N-terminus to the C-terminus, an HBV core polypeptide and the HBV polymerase deletion mutant polypeptide, as described herein. In some embodiments, HBV polymerase deletion mutant polypeptide further comprises (e.g., is a fusion protein including) an HBV core polypeptide. In some embodiments, the HBV polymerase deletion mutant polypeptide comprises in sequential order from the N-terminus to the C-terminus, a terminal protein (TP) domain, an inactivated reverse transcriptase domain, and an inactivated RNase H, wherein the mutant polypeptide does not comprise all or part of a Spacer domain. [Extracted from the article]

Keywords: Autism; Developmental Disabilities; Developmental Diseases and Conditions; Genetics; Health and Medicine; Mental Health; Mental Health Diseases and Conditions; Neurology; Neuroscience; The Florey Institute of Neuroscience and Mental Health EN Autism Developmental Disabilities Developmental Diseases and Conditions Genetics Health and Medicine Mental Health Mental Health Diseases and Conditions Neurology Neuroscience The Florey Institute of Neuroscience and Mental Health 2368 2368 1 08/21/23 20230821 NES 230821 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- The Florey Institute of Neuroscience and Mental Health (Parkville, Australia) has been issued patent number 11713463, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. Autism, Developmental Disabilities, Developmental Diseases and Conditions, Genetics, Health and Medicine, Mental Health, Mental Health Diseases and Conditions, Neurology, Neuroscience, The Florey Institute of Neuroscience and Mental Health. [Extracted from the article]

The method of claim 1, wherein the first substrate comprises a plurality of capture probes, and wherein each capture probe of the plurality of capture probes comprises the capture domain. "In another aspect, this disclosure features methods for enhancing the specificity of binding of a capture probe binding domain to a capture domain including: (a) contacting a biological sample with a substrate including a plurality of capture probes, wherein a capture probe of the plurality of capture probes includes a spatial barcode and the capture domain; (b) binding an analyte-binding moiety to the analyte, wherein the analyte-binding moiety is associated with an oligonucleotide including an analyte-binding-moiety barcode and the capture probe binding domain that hybridizes to the capture domain, wherein all or a portion of the capture probe binding domain is hybridized to a blocking probe; and (c) releasing the blocking probe from the capture probe binding domain, thereby allowing the capture probe binding domain to hybridize to the capture domain; thereby enhancing the specificity of binding of the capture probe binding domain to the capture domain." The method of claim 14, wherein the first substrate comprises a plurality of capture probes, and wherein each capture probe of the plurality of capture probes comprises the capture domain. [Extracted from the article]

Keywords: Tianjin; People's Republic of China; Asia; Antisense Technology; Bioengineering; Biotechnology; Cancer; Cancer Gene Therapy; Drugs and Therapies; Enzymes and Coenzymes; Gene Therapy; Genetics; Oncology; Pharmaceuticals; Therapy EN Tianjin People's Republic of China Asia Antisense Technology Bioengineering Biotechnology Cancer Cancer Gene Therapy Drugs and Therapies Enzymes and Coenzymes Gene Therapy Genetics Oncology Pharmaceuticals Therapy 50 50 1 07/31/23 20230803 NES 230803 2023 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology - Cancer Gene Therapy. Herein, a dual-enzyme-responsive DNA-based nanoframework (NF) that enables controlled co-delivery of Cas9 ribonucleoprotein (RNP) and antisense oligodeoxynucleotide (ASO) for synergistic gene therapy is reported.". [Extracted from the article]

These RNA-binding molecules themselves are also DNA-based strands and are called oligonucleotides that, by exploiting the Watson-Crick base-pairing model, recruit the target RNA thus impeding its functioning. Lastly, the oligonucleotide should produce hybrids that are sensitive to RNase H degradation, which is the cellular mechanism responsible for removing RNA molecules and preventing protein formation. Keywords: Bioengineering; Biomedicine; Biotechnology; Drugs and Therapies; Genetics; Health and Medicine; Institute for Research in Biomedicine (IRB Barcelona); Pharmaceuticals; Technology; Therapeutics; Therapy EN Bioengineering Biomedicine Biotechnology Drugs and Therapies Genetics Health and Medicine Institute for Research in Biomedicine (IRB Barcelona) Pharmaceuticals Technology Therapeutics Therapy 313 313 1 05/29/23 20230509 NES 230509 2023 JUN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Researchers at IRB Barcelona and the biotech Nostrum Biodiscovery, with the collaboration of other companies such as Biogen, and Ionis have laid the groundwork for the systematic development of optimal RNA-binding inhibitors based on antisense oligonucleotide technology. [Extracted from the article]

"In certain exemplary embodiments, the target-recognition sequence has the formula A-B-C, wherein A comprises from about 0 to about 8, from about 2 to about 6, or about 3 modified nucleotides, B comprises from about 4 to about 18, from about 6 to about 12, or about 9 deoxyribonucleic acid (DNA) nucleotides and/or DNA-like nucleotides, and C comprises from about 0 to about 8, from about 2 to about 6 or about 3 modified nucleotides, and the overall length of the ASO is from about 10 to about 30 nucleotides. The bicyclic nucleotide can optionally be selected from the group consisting of a locked nucleotide, an ethyl-constrained nucleotide, an alpha-L-locked nucleic acid, and a tricyclo-DNA, or any combination thereof. Keywords: Biotechnology; Cancer; Cancer Gene Therapy; Drugs and Therapies; Enzymes and Coenzymes; Gene Therapy; Genetics; Nuclease; Oncology; Patent Application; Pharmaceuticals EN Biotechnology Cancer Cancer Gene Therapy Drugs and Therapies Enzymes and Coenzymes Gene Therapy Genetics Nuclease Oncology Patent Application Pharmaceuticals 42 42 1 04/17/23 20230417 NES 230417 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A patent application by the inventors Haitchi, Hans Michael (Southampton, GB); Pendergraff, Hannah (Kongens Lyngby, DK); Watts, Jonathan (Worcester, MA, US), filed on June 27, 2022, was made available online on March 30, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "In certain exemplary embodiments, each of the modified nucleotides is independently selected from the group consisting of a bicyclic nucleotide, and a 2'-modified nucleotide, optionally wherein A comprises from about 2 to about 4 or about 3 locked nucleotides, B comprises from about 8 to about 12 or about 9 DNA-like nucleotides, and C comprises from about 2 to about 4 or about 3 locked nucleotides. [Extracted from the article]

Cancer, Health and Medicine, Oncology Keywords: Cancer; Health and Medicine; Oncology EN Cancer Health and Medicine Oncology 892 892 1 03/23/23 20230321 NES 230321 2023 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on cancer are presented in a new report. [Extracted from the article]